Matinas Biopharma (MTNB) vs VivoSim Labs (VIVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
VivoSim Labs is the larger company by market cap ($2.9 million vs $2.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MTNB | VIVS |
|---|---|---|
| Share price | $2.83 | $0.1772 |
| Market cap | $2.77M | $2.94M |
| 1-day change | +2.17% | -7.47% |
| EPS (TTM) | $-17.55 | $-4.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.95 | $3.54 |
| 52-week low | $2.27 | $0.1746 |
| Distance from 52-week high | -90.22% | -94.99% |
| Average volume | 405.99K | 5.84M |
| Shares outstanding | 979.52K | 16.59M |
| Employees | 2 | 15 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Matinas Biopharma
MTNB stock →Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Healthcare · Biotechnology · 2 employees
About VivoSim Labs
VIVS stock →VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models.
Healthcare · Biotechnology · 15 employees
MTNB vs VIVS FAQ
Which is bigger, Matinas Biopharma or VivoSim Labs?
VivoSim Labs (VIVS) is larger, with a market capitalization of $2.94M compared with $2.77M for Matinas Biopharma (MTNB).
Are Matinas Biopharma and VivoSim Labs in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.